Expression of breast cancer specific gene-1 (BCSG-1/gamma-synuclein) is associated with tumour grade but not with clinical outcome of patients with breast cancer.
This study examined the expression and distribution of BCSG-1 in human breast cancer tissue. IHC revealed that BCSG-1 was primarily seen as a cytosolic protein, weakly staining normal mammary epithelial cells but increased in breast tumour cells. Q-PCR revealed that node negative and positive tumours had similar levels of BCSG-1 transcript and BCSG-1/CK19 ratio. There were significantly higher levels in grade 2 and grade 3 tumours compared to grade 1. Patients with NPI (Nottingham prognostic indicator) < 3.4, had a predicted 80% 15-year survival. After a 10-year follow-up, no significant difference was seen between tumours from patients remaining disease-free and those who died of breast cancer. The levels of BCSG-1 significantly correlated with an associated molecule, transglutaminase-3 (r = 0.307, P < 0.05), and weakly with transglutaminase-7 (r = 0.183). BCSG-1 is increased in breast tumour cells, is negatively associated with tumour grade and significantly correlates with levels of transglutaminase-3.
Martin
Tracey A
TA
Metastasis and Angiogenesis Research Group, Wales College of Medicine, Cardiff University, Heath Park, Cardiff, CF4 4XN, UK. martinta1@cf.ac.uk
Gomez
Kelvin
K
Watkins
Gareth
G
Douglas-Jones
Anthony
A
Mansel
Robert E
RE
Jiang
Wen G
WG
D001943:Breast Neoplasms / Q000235:genetics*; D017931:DNA Primers / Q000737:chemistry; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009362:Neoplasm Metastasis; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D013997:Time Factors; D011503:Transglutaminases / Q000096:biosynthesis; D016896:Treatment Outcome; D051845:gamma-Synuclein / Q000096:biosynthesis*
D017931:DNA Primers; D012333:RNA, Messenger; D051845:gamma-Synuclein; C498712:TGM3 protein, human; D011503:Transglutaminases